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Background. P. falciparum gametocytes may persist after treatment with sulphadoxine-pyrimethamine (SP) plus artesunate
(AS) and contribute considerably to malaria transmission. We determined the efficacy of SP+AS plus a single dose of
primaquine (PQ, 0.75 mg/kg) on clearing gametocytaemia measured by molecular methods. Methodology. The study was
conducted in Mnyuzi, an area of hyperendemic malaria in north-eastern Tanzania. Children aged 3–15 years with
uncomplicated P. falciparum malaria with an asexual parasite density between 500–100,000 parasites/mL were randomized
to receive treatment with either SP+AS or SP+AS+PQ. P. falciparum gametocyte prevalence and density during the 42-day
follow-up period were determined by real-time nucleic acid sequence-based amplification (QT-NASBA). Haemoglobin levels
(Hb) were determined to address concerns about haemolysis in G6PD-deficient individuals. Results. 108 individuals were
randomized. Pfs25 QT-NASBA gametocyte prevalence was 88–91% at enrolment and decreased afterwards for both treatment
arms. Gametocyte prevalence and density were significantly lower in children treated with SP+AS+PQ. On day 14 after
treatment 3.9% (2/51) of the SP+AS+PQ treated children harboured gametocytes compared to 62.7% (32/51) of those treated
with SP+AS (p,0.001). Hb levels were reduced in the week following treatment with SP+AS+PQ and this reduction was related
to G6PD deficiency. The Hb levels of all patients recovered to pre-treatment levels or greater within one month after
treatment. Conclusions. PQ clears submicroscopic gametocytes after treatment with SP+AS and the persisting gametocytes
circulated at densities that are unlikely to contribute to malaria transmission. For individuals without severe anaemia, addition
of a single dose of PQ to an efficacious antimalarial drug combination is a safe approach to reduce malaria transmission
following treatment. Trial Registration. Controlled-Trials.com ISRCTN61534963
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INTRODUCTION
The majority of anti-malarial drug treatments target the asexual
blood stages of Plasmodium falciparum that are responsible for clinical
disease and death. Sexual stage parasites, gametocytes, can also be
present in infected individuals and are responsible for the trans-
mission of the parasite to mosquitoes. Drugs specifically targeting
these sexual stage parasites may affect the spread of malaria in the
human population. Anti-gametocyticidal drugs are used by several
countries to prevent onward transmission from clinical malaria cases
[1] and have also been evaluated by mass drug administration to
reduce malaria transmission in communities [2].
Artemisinin-based combination therapies (ACT) are advocated
as first-line antimalarial treatment because of their high treatment
efficacy [3–7] and beneficial effects on malaria transmission [4–7].
Although ACT efficiently reduces microscopic levels of gameto-
cytes [4–7], submicroscopic gametocytes (detected by molecular
analysis) may persist after treatment and allow post-treatment
malaria transmission [4]. The implementation of ACT may have
a beneficial influence on malaria transmission in the general
population [8] but ACT may not be sufficient to completely
prevent post treatment malaria transmission. Primaquine (PQ)
may be of added value in attempts to block malaria transmission as
part of a mass drug administration. PQ is an 8-aminoquinolone
that is widely used for the treatment of P. vivax malaria and actively
clears mature P. falciparum gametocytes [9–11]. Although there is
no consensus about which drug is the most potent gametocytocidal
drug [10,11], artesunate (AS) may predominantly inhibit game-
tocyte development while PQ may accelerate gametocyte
clearance [11]. In combination with sulphadoxine-pyrimethamine
(SP) and AS, PQ was found to be safe and highly efficacious in
clearing asexual parasites and P. falciparum gametocytes detected
by microscopy [12]. The efficacy of this combination on
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1023submicroscopic gametocytaemia is unknown and, in general,
information on PQ use in Africa is scarce. Prior to the wide-scale
introduction of ACT, a single dose of PQ following first line
antimalarial treatment was recommended by the World Health
Organisation to reduce malaria transmission in low endemic areas
[1]. Although several countries adopted this recommendation, there
is concern for negative haemolytic side effects in individuals who are
glucose-6-phosphate-dehydrogenase (G6PD) deficient [1,10].
Here, we determine the safety and efficacy of SP+AS plus
a single dose of PQ on clearing submicroscopic levels of P.
falciparum gametocytaemia in an area of hyperendemic malaria in
north eastern Tanzania. Possible haemolytic effects of PQ were
determined in relation to G6PD status.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The trial was registered at Current Controlled
Trials; ISRCTN61534963; http://www.controlled-trials.com/
ISRCTN61534963/. Registration was done after patient recruit-
ment started due to communication problems.
Participants
This study was conducted in the period July through September
2006 in Mnyuzi, a rural village in the Tanga Region, north eastern
Tanzania. Malaria transmission intensity is high with an estimated
entomological inoculation rate (EIR) of 91 infectious bites per
person per year [13]. The rainfall pattern is bimodal, with a long
rainy season between March and June, and a short rainy season
between October and December. The study protocol was
approved by the ethics committees of Kilimanjaro Christian
Medical Centre, the Tanzanian National Institute for Medical
Research (NIMR/HQ/R.8a Vol. XIII/446) and the London
School of Hygiene and Tropical Medicine (#4097). Participants
were recruited from among children consulting the Mnyuzi health
centre and who were resident within a 10 kilometres radius.
Informed consent was obtained form the child’s parents or
guardians prior to inclusion. Children aged 3–15 years with
a temperature .37.5Cu or a history of fever within the last
48 hours and with P. falciparum mono-infection at a density
between 500–100,000 parasites/mL were eligible for recruitment.
Exclusion criteria were: a haemoglobin (Hb) concentration
measured by HemocueH below 8g/dL, inability to take drugs
orally, known hypersensitivity to any of the drugs given, reported
treatment with antimalarial chemotherapy in the past 2 weeks,
evidence of chronic disease or acute infection other than malaria,
domicile outside the study area, signs of severe malaria and
eligibility for other malaria studies conducted in the region.
Interventions
Participants enrolled were randomized to one of the two treatment
regimes:
(a) Sulphadoxine (25 mg/kg) and pyrimethamine (1.25 mg/kg)
as a single dose (SP; FansidarH, Roche, Switzerland) plus
artesunate (AS), 4 mg/kg once daily for three days
(ArsumaxH, Sanofi-aventis, France) plus placebo once on
the third day (Organon, The Netherlands);
(b) SP plus AS plus primaquine (base; department of clinical
pharmacology, Radboud University Nijmegen Medical
Centre, the Netherlands) as a single dose on the third day
(0.75 mg/kg). Primaquine capsules were produced following
regulations of the European Pharmacopeia.
Treatment was administered by staff at the recruitment clinic.
Each child was observed for 30 minutes after treatment, a re-
placement dose was given in case of vomiting. None of the
children had repeated vomiting. Paracetamol (10 mg/kg) was
given until symptoms had subsided. In case of parasitological
treatment failure, rescue treatment with mefloquine was admin-
istered (LariamH, Roche, Switzerland; 15 mg/kg on first day and
10 mg/kg on second day). All staff engaged in the trial were
blinded as to the treatment group of each child, apart from the
study physician who administered medication.
Objectives
Our primary objectives were to determine the effect of SP+AS and
SP+AS+PQ on submicroscopic P. falciparum gametocyte prevalence
and density and to determine the safety of a single dose of PQ in
glucose-6-phosphate-dehydrogenase (G6PD) deficient children.
Outcomes
The primary outcomes were gametocyte prevalence and density
by real-time nucleic acid sequence-based amplification (QT-
NASBA). The secondary outcome was haemoglobin concentration
following treatment. Other outcomes that we evaluated were
microscopic gametocyte prevalence, treatment efficacy and the
occurrence of side effects.
Participants were encouraged to attend the recruiting clinic at day
1, 2, 3, 7, 14, 28 and 42 after enrolment and at any time the child
became unwell.On each day offollow-up, tympanictemperature was
measured by electric thermometer and a finger prick blood sample
was used for haemoglobin (Hb) measurement using a Hemocue
photometer (Angelholm, Sweden), a microscopic slide, a 50 mL-
blood sample for real-time nucleic acid sequence-based amplification
(QT-NASBA) and a filter paper sample. The presence of symptoms
suggestive of anaemia (fatigue, weakness, dizziness, headache, heart
palpitations) or allergic drug reactions (rash) was assessed verbally
during every follow-up visit. Field assistants visited the homes of
children who failed to show up to collect additional samples.
Blood smears were stained for 10 minutes with 10% Giemsa
and screened for asexual parasites and gametocytes at enrolment
and on day 3, 7, 14, 28 and 42 after treatment. All slides were
double-read by experienced microscopists and were declared
negative if no parasites were observed in 100 microscopic fields.
Readings were compared for validation and slides giving discordant
results were read by a third reader. The majority result was taken as
final in the case of positive versus negative results and geometric
mean of the two closest values for density discordants . Asexual
parasites and gametocytes were counted against 200 and 500 white
blood cells, respectively and converted to parasites/mLb ya s s u m i n g
a density of 8000 white blood cells/mL blood.
P. falciparum parasite detection by QT-NASBA was performed as
described previously [14,15]. Briefly, nucleic acids were extracted
from50 mL-blood sampleswith initial RNA extraction carried outin
the field following the original Guanidine isothiocyanate (GuSCN)
RNA extraction method [16] until the nucleic acids were bound to
silica dioxide particles. At this point, samples were stored at 220uC
prior to completion of the extraction and QT-NASBA analysis. QT-
NASBA was performed on a NucliSens EasyQ analyser (bioMe ´r-
ieux, Boxtel, the Netherlands) for Pfs25 mRNA. The Pfs25 QT-
NASBA is gametocyte-specific and has a detection limit of 10–100
gametocytes/mL. Nuclisens Basic kits (bioMe ´rieux, Boxtel, the
Netherlands) were used for amplification according to the
manufacturers instructions. A standard dilution series of in vitro
cultured mature NF54 gametocytes was included in each run to
ascertain gametocyte density [17].
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DNA extraction and PCR genotype analysis DNA extraction
from bloodspots on filter paper was carried out by the chelex-100
method as described by Wooden et al. [18] with some modifications
described in Pearce et al. [19]. In brief, all samples were extracted in
a 96-well plate format. The bloodspot was first soaked in phosphate-
buffered saline (PBS) with 0.5% saponin overnight and was then
washed twice in 1 ml of PBS. The samples were then boiled for
8 min in 100 mLo fH 2Oa n d5 0mL of 20% chelex suspension in
distilled water (pH 9.5) and centrifugated at 5000 rpm for
10 minutes. 1 mL of supernatant was used in the PCR reactions.
Genotyping for MSP-1, MSP-2 and glucose-6-phosphate-
dehydrogenase (G6PD) deficiency To differentiate between
recrudescent parasites i.e. those persisting from the initial infection
and parasites from a new infection, a nested PCR amplification of
the polymorphic regions of P. falciparum genes msp1 (K1, MAD20
and RO33) and msp2 (IC1 and FC27) was performed as described
by Snounou et al [20]. This PCR was performed for follow-up
samples with microscopically confirmed parasitaemia. The PCR
products (10 mL) were run in electrophoresis on 2–2.5% metaphor
agarose gels in 1xTBE buffer, stained with ethidium bromide and
then visualized in UV trans-illumination. The procedure of
Cattamanchi et al. was followed in that indeterminate samples
for which a majority of novel bands appeared for the post-
treatment infection were scored as new infections [21].
G6PD deficiency was determined by screening human DNA for
single nucleotide polymorphisms in the G6PD gene (G202A,
A376G) by a simple high throughput method using PCR,
sequence specific oligonucleotide probes (SSOPs) and ELISA-
based technology [22]. Individuals with no G202A mutation were
classified G6PD B, heterozygotes for the G202A mutation were
classified G6PD A and homozygote or hemizygote (males) for the
G202A mutation were classified G6PD A-.
Sample size
The primary endpoint used for sample size calculation was Pfs25
QT-NASBA gametocyte prevalence after treatment. Assuming
a gametocyte prevalence in the SP+AS group of 50% on day 14
after treatment [4], a sample size of 50 individuals per group
would allow over a power of 80% to detect a reduction in
gametocyte prevalence to 20% in the SP+AS+PQ group, allowing
for 5% drop-out and using a significance level of 0.05. This sample
size also allowed us to detect a two-fold reduction in gametocyte
prevalence during the entire period of follow-up in longitudinal
data analyses, assuming an average Pfs25 QT-NASBA gametocyte
prevalence of 58% in SP+AS treated children [4], and a maximum
correlation between observations of the same individual of 0.30.
Randomization
The randomization sequence was generated in Stata 8.0 (Stata
Corporation, Texas, USA) using restricted randomization with
a block size of 20. Treatment allocation was determined by
opening pre-prepared randomization envelopes in sequence by the
study physician. The same physician was involved in participant
selection and clinical evaluation. Parasite carriage by microscopy
and Pfs25 QT-NASBA and haemoglobin concentrations were
determined by technicians who were unaware of the treatment
allocated to study participants.
Statistical methods
Therapeutic outcome was classified as early parasitological
treatment failure (ETF), late treatment failure (LTF), re-infection
or adequate clinical and parasitological response (ACPR) [23].
Haemoglobin concentrations during follow-up were expressed as
a percentage of the enrolment concentration. To quantify the
effect of treatment on gametocyte densities, we determined the
area under the curve (AUC) of Pfs25 QT-NASBA gametocyte
density versus time [24,25]. This measure incorporates both the
magnitude and the duration of gametocyte carriage and was
described by Me ´ndez et al. [25]. The AUC from days 0–42 was
calculated as: AUC=[(320)6(g0+g3)/2+(723)6(g3+g7)/
2+(1427)6(g7+g14)/2+(28214)6(g14+g28)/2+(42228)6(g28+g42)/
2]/42; where gd represents Pfs25 QT-NASBA gametocyte density
on day d. Gametocyte negative samples were included as zeroes.
The measure was scaled by 42 so that it represents AUC per day
and this was transformed by log10. Microscopic and QT-NASBA
parasite densities were analysed after log10-transformation.
Because we were interested in clearance of gametocytes of the
original infection, slides from individuals in which PCR analysis
defined a new infection were excluded from analyses on post-
treatment gametocyte prevalence and density.
Proportions were compared using the chi-squared statistic for
a 2-by-2 contingency table. Normally-distributed continuous
variables were compared using the Student t-test. Variables that
were not normally distributed were compared using the Wilcoxon
rank-sum test. Multiple linear regression models were used in case
of continuous variables to adjust for potential confounding factors
such as asexual parasite and gametocyte density at enrolment.
Multiple logistic regression models with Generalized Estimating
Equations (GEE) were used to test the influence of treatment on
dichotomous variables with multiple observations per participant,
such as gametocyte prevalence during follow-up. Estimates were
adjusted for potential confounding factors and a random effect was
included in the models to allow for correlations within individuals.
Regression coefficients (b) were calculated for continuous de-
pendent variables and odds ratios (OR) for dichotomous dependent
variables, both with 95% confidence intervals (95% CI). Statistical
analyses were performed using SPSS for Windows 12.0 (SPSS Inc.,
Chicago, USA) and Stata 8.0 (Stata Corporation, Texas, USA).
RESULTS
Recruitment and Participant Flow
A total of 108 children were randomised over the two treatment
arms (figure 1). This number exceeds the original sample size (100)
because of a high number of patients appearing on the last day of
enrolment. Two children (1.9%) were lost for evaluation during
the 42-day follow-up period, one in each treatment arm. Parasite
density, gametocyte prevalence, haemoglobin concentrations,
fever prevalence and the proportion of G6PD-deficient children
at enrolment were not different between the treatment regimens
(table 1). Adequate clinical and parasitological response (ACPR)
on day 42 after treatment was observed in 71.7% (38/53) of the
children treated with SP+AS and in 67.9% (36/53) of those
treated with SP+AS+PQ (x
2=1.70; p=0.64)(table 2).
Outcomes and Estimation: Gametocyte carriage
after treatment
Microscopic gametocyte prevalence at enrolment was 26.4% (14/
53) for children treated with SP+AS and 18.9% (10/53) for
children treated with SP+AS+PQ (table 1). Microscopic gameto-
cyte prevalence decreased after treatment in both treatment arms
(figure 2A) and was significantly lower in individuals treated with
SP+AS+PQ compared to those treated with SP+AS when the
entire period of follow-up was considered, after adjustment for
enrolment gametocyte prevalence (GEE: OR=0.17 (95%
Primaquine Clears Gametocytes
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was seen on day 7 and 14 after treatment with SP+AS+PQ.
Enrolment gametocyte prevalence defined by Pfs25 QT-
NASBA was 88.2% (45/51) for SP+AS treated individuals
compared to 90.6% (48/53) for SP+AS+PQ treated children
(table 1). Predictably, children with microscopically confirmed
gametocytes at enrolment had a significantly higher median Pfs25
QT-NASBA gametocyte density (46.6 gametocytes/mL; IQR
8.9–346.5) compared to those gametocyte-free by microscopy
(7.5 gametocytes/mL; IQR 3.1–67.5)(Wilcoxon Rank-Sum test
z=22,01, p=0.04).
Pfs25 QT-NASBA gametocyte density was not initially defined
as outcome measure, but densities were compared between the
treatment arms post-hoc. At the time of enrolment Pfs25 QT-
NASBA gametocyte density was 28.8 gametocytes/mL (IQR 6.9–
109.9 gametocytes/mL) for SP+AS treated children compared to
17.5 gametocytes/mL (IQR 1.1–76.9) for SP+AS+PQ treated
children (table 1). During follow-up Pfs25 QT-NASBA gametocyte
prevalence decreased for both SP+AS and SP+AS+PQ treated
children (figure 2B and table 3). After adjustment for enrolment
Pfs25 QT-NASBA gametocyte density, Pfs25 QT-NASBA game-
tocyte prevalence was lower in individuals treated with
SP+AS+PQ during the entire period of follow-up (GEE:
OR=0.27 (95% CI=0.18–0.40), p,0.001). The Pfs25 QT-
NASBA gametocyte density in gametocyte positive samples was
consistently lower for SP+AS+PQ treated children during follow-
up (table 3). The average duration of gametocyte carriage was
summarised in the area under the curve of Pfs25 QT-NASBA
gametocyte density versus time (table 4). The area under the curve
was significantly lower for SP+AS+PQ treated children (t-test
t=3.28, p ,0.001), as were the number of sampling times when
gametocytes were detected (GEE: OR=0.27 (95% CI=0.18–
0.40), p,0.001) and the geometric mean gametocyte density in
gametocyte positive samples (GEE: b=20.40 (95% CI=
20.74220.07), p=0.02).
Most treatment failures or re-infections appeared after day 14
(table 2). It is therefore appropriate to focus on the first two weeks
after treatment to determine the effect of treatment in the absence
of treatment failure or re-infection. On day 14 after SP+AS
treatment, 32 (62.7%) individuals were gametocyte positive
with a mean gametocyte density of 4.5 gametocytes per mL
(IQR 1.8–37.1)(table 3). Only two individuals (3.9%) were positive
by Pfs25 QT-NASBA on day 14 after treatment with SP+AS+PQ
with low gametocyte densities of 0.067 and 0.094 gametocytes
per mL.
Figure 1. Profile of the study
doi:10.1371/journal.pone.0001023.g001
Table 1. Characteristics of the study population at enrolment
......................................................................
SP+AS SP+AS+PQ
N5 4 5 4
Age, median (IQR) 5 (3–8) 5.5 (3–10)
Sex, % male (n/N) 46.3 (25/54) 55.6 (30/54)
Temperature, % fever (.37.5uC)
(n/N)
30.2 (16/53) 35.8 (19/53)
Asexual parasite density GM/mL
(IQR)
4,759 (959–22,248) 7,379 (2,334–25,304)
Microscopic gametocyte
prevalence, % (n/N)
26.4 (14/53) 18.9 (10/53)
Pfs25 QT-NASBA gametocyte
prevalence, % (n/N)
88.2 (45/51) 90.6 (48/53)
Pfs25 QT-NASBA gametocyte
density, GM/mL (IQR)
*
28.8 (6.9–109.9) 17.5 (1.1–76.9)
G6PD, % (n/N)
B 68.5 (37/54) 75.5 (40/53)
A 25.9 (14/54) 17.0 (9/53)
A- 5.6 (3/54) 7.5 (4/53)
Haemoglobin concentration,
g/dL, median (IQR)
10.5 (9.4–11.8) 10.8 (9.8–11.8)
IQR=interquartile range; GM=geometric mean; G6PD: B=no G202A mutation;
A=heterozygotes, single G202A mutation; A-=homozygote or hemizygote
(males), only G202A mutations.
*For gametocyte carriers only.
doi:10.1371/journal.pone.0001023.t001
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Table 2. Treatment outcome for the different treatment
regimens on day 14, 28 and 42.
......................................................................
SP+AS SP+AS+PQ
Number evaluated 53 53
Day 14 Treatment outcome, % (n)
ACPR 98.1 (52) 100.0 (53)
ETF 0 (0) 0
LTF 0 (0) 0
Re-infection 1.9 (1) 0
Indeterminate 0 (0) 0
Day 28 Treatment outcome, % (n)
ACPR 77.4 (41) 83.0 (44)
ETF 0 (0) 0 (0)
LTF 3.8 (2) 5.7 (3)
Re-infection 15.1 (8) 9.4 (5)
Indeterminate 3.8 (2) 1.9 (1)
Day 42 Treatment outcome, % (n)
ACPR 71.7 (38) 67.9 (36)
ETF 0 (0) 0 (0)
LTF 3.8 (2) 9.4 (5)
Re-infection 17.0 (9) 13.2 (7)
Indeterminate 7.5 (4) 9.4 (5)
ACPR=adequate clinical and parasitological response, ETF=early treatment
failure, LTF=late treatment failure. Indeterminate=indeterminate due to PCR-
failure (n=1) or missing filter paper DNA samples (n=8).
doi:10.1371/journal.pone.0001023.t002
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To address concerns about haemolysis associated with PQ use in
G6PD deficient individuals, Hb concentration was assessed at
enrolment and during follow-up. Median Hb at enrolment was
10.5 g/dL (IQR 9.4–11.8) for SP+AS treated children and 10.8 g/
dL (9.8–11.8) for SP+AS+PQ treated children (table 1). While Hb
relative to enrolment concentration gradually increased in the
weeks after treatment with SP+AS, it first decreased for
SP+AS+PQ treatment and remained lower up to day 14
(figure 3). The relative decrease was most pronounced on day 7
after SP+AS+PQ treatment when Hb concentration was 5.2%
lower (95% CI 28.4–21.8) than on enrolment (paired t-test:
t=2.86; p=0.006). When only children with the G6PD B variant
were considered, the relative decrease in Hb concentration on day
7 after treatment with SP+AS+PQ was no longer statistically
significant (paired t-test: t=1.57; p=0.12).
The reduction in Hb shortly after SP+AS+PQ treatment was
most pronounced in children with the G6PD A- variant (figure 4)
although numbers were too small to allow statistical comparisons.
None of the children developed clinical symptoms related to
anaemia or an Hb below 5g/dL. The Hb concentrations on day
28 and day 42 after treatment were equal to or greater than that at
enrolment for all G6PD categories (figure 4). Eight children
experienced $20% reduction in Hb concentration on day 7
relative to that at enrolment, compared to none in the SP+AS
treatment arm. The range of Hb concentration in these eight
individuals was 5.4–10.4 g/dL on day 7 after SP+AS+PQ
treatment. Two of the children with $20% reduction in Hb
concentration on day 7 had the G6PD A- variant (25%), one
had the G6PD A variant (12.5%) and the other five had G6PD B
variant (62.5%). None of the children reported symptoms
suggestive of anaemia or allergic drug reactions during
follow-up.
Figure 2. Gametocyte prevalence by microscopy (A) and Pfs25 QT-NASBA (B). Gametocyte prevalence for SP+AS (closed diamonds, solid line) and
SP+AS+PQ (open triangles, broken lines) treated children. Bars indicate the 95% confidence intervals around the proportions. * indicates a statistically
significant difference between the two treatment arms.
doi:10.1371/journal.pone.0001023.g002
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Interpretation
This study shows that a single dose of primaquine (PQ) is of
significant additive value in clearing gametocytes in an area of
high malaria endemicity in Tanzania. Only 3.9% of children
treated with SP+AS+PQ had gametocytes on day 14 after
successful treatment compared to 62.7% for SP+AS treated
children. Gametocytes persisting on day 14 after SP+AS+PQ
treatment circulated at densities well below the theoretical
threshold for mosquito infection.
Gametocyte carriage after treatment with SP+AS persisted for
more than one month and more than two-thirds of the treated
individuals harboured gametocytes on day 14. These data confirm
previous findings [26]. The addition of a single dose of PQ to this
regime significantly reduced gametocyte carriage. When micros-
copy was used as tool to detect gametocytes, no gametocytes were
observed seven days after the initiation of treatment with
SP+AS+PQ. On day 28 after treatment, gametocytes were
detected in only one individual. Submicroscopic gametocyte
prevalence decreased to 3.9% (2/51) on day 14 after initiation
of treatment but increased at subsequent follow up time points.
Table 3. Pfs25 QT-NASBA gametocyte prevalence and density after treatment with SP+AS and SP+AS+PQ.
..................................................................................................................................................
SP+AS SP+AS+PQ
Gametocyte prevalence, % (n/N) Gametocyte density/mL, GM (IQR) Gametocyte prevalence, % (n/N) Gametocyte density/mL, GM (IQR)
Day 0 88.2% (45/51) 28.8 (6.9–109.9) 90.6% (48/53) 17.5 (1.1–76.9)
Day 3 80.8% (42/52) 25.5 (4.2–132.9) 53.8% (28/52) 2.9 (0.6–36.6)
Day 7 71.7% (38/53) 8.0 (1.8–59.1) 15.7% (8/51) 0.3 (0.02–2.4)
Day 14 62.7% (32/51) 4.5 (1.8–37.1) 3.9% (2/51) 0.07&0.09
Day 28 41.9% (18/43) 10.9 (1.0–70.0) 10.4% (4/46) 3.8 (0.2–2.4)
Day 42 28.2% (11/39) 17.4 (1.2–191.4) 16.3% (5/40) 7.9 (0.5–54.3)
GM=geometric mean Pfs25 QT-NASBA gametocyte density per microlitre for gametocyte carriers only; IQR=interquartile range
doi:10.1371/journal.pone.0001023.t003
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Table 4. Effect of treatment on gametocyte carriage during follow-up
..................................................................................................................................................
SP+AS SP+AS+PQ p-value
Mean AUC of gametocyte density/mL versus time, (IQR) 11.1 (2.2–53.8) 1.5 (0.3–8.8) ,0.001
*
Number of sampling times when gametocytes were detected, % (n/N) 64.4 (186/289) 32.4 (95/293) ,0.001
{
GM gametocyte density/mL on days when gametocytes were detected, (IQR) 15.8 (4.1–85.8) 5.8 (0.8–55.1) 0.02
{
AUC=area under the curve; GM=geometric mean; IQR=interquartile range
*Adjusted for gametocyte density at enrolment;
{ adjusted for correlations between observations from the same individual
doi:10.1371/journal.pone.0001023.t004
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Figure 3. Haemoglobin concentration following treatment. Concentrations are expressed relative to that at enrolment for SP+AS (closed diamonds,
solid line) and SP+AS+PQ (open triangles, broken lines). Bars indicate the 95% confidence intervals around the proportions. * indicates a statistically
significant difference between the two treatment arms.
doi:10.1371/journal.pone.0001023.g003
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new infections that were undetected by microscopy. Treatment
failure rates were similar to those reported in recent drug efficacy
studies in east Africa [3,4,27] and re-infection rates were high in
this area of intense malaria transmission. As a consequence, 28.3%
of the SP+AS treated children and 32.1% of the SP+AS+PQ
treated children experienced microscopically confirmed treatment
failure or re-infection during follow-up. True treatment failure and
re-infection rates may be higher as not all asexual parasites will be
detected by microscopy. A high persistence of submicroscopic
asexual parasites after apparently successful drug treatment has
been described [28], as well as the acquisition of new sub-patent
infections [29]. Gametocytes that newly developed from new or
persisting asexual infections are therefore likely to be responsible
for the increase in gametocyte prevalence after day 14 that has
been reported previously [5].
Focusing on the first two weeks after initiation of treatment, PQ
seems to decrease the number of gametocytes rapidly to a level
where onward transmission may be arrested completely. Although
analyses on gametocyte densities should be considered as post-hoc
analyses and we did not directly determine post-treatment
malaria transmission, it is clear that the transmission potential is
reduced in children treated with SP+AS+PQ. Gametocyte
prevalence and density were lower in children treated with
SP+AS+PQ and gametocytes persisting on day 14 after treatment
circulated at densities below 0.1 gametocyte/mL. When assuming
an average mosquito blood meal size of 2–3 mL [30], these
concentrations are unlikely to result in mosquito infection,
although infectiousness of very low gametocyte densities can not
be excluded [31].
Generalisability
The rationale for using PQ in P. falciparum infections is to reduce
post-treatment infectivity (as routinely practiced in several
countries in Asia and the Americas [1]) and as a quarantine
treatment to reduce the spread of (drug resistant) parasites. The
aim of the current study was not to determine if PQ should be
routinely added to current ACT regimens. The objective was to
explore if PQ is a valuable component in mass drug administration
studies that aim to reduce malaria transmission. Mass drug
administration (MDA) studies are typically conducted in areas of
low malaria transmission intensity and also include asymptomatic
parasite carriers. The likelihood of re-infection is lower in these
areas and the effect of PQ can be expected to be larger because
enrolment gametocyte densities are lower.
In MDA studies, drugs are administered to asymptomatic
individuals, raising safety concerns over the haemolytic effect of
PQ on individuals with G6PD mutations. Due to the potential
protective effect of G6PD-deficiency from malaria, G6PD de-
ficiency is probably selected in malaria endemic regions, in
a similar manner as for other haemoglobinopathies [32]. In our
population, 6.5% (7/107) of the children had the A- variant of
G6PD deficiency. We observed that the addition of PQ resulted in
a statistically significant but transient reduction in haemoglobin
levels, as was previously reported for PQ administered at a curative
dose (0.5 mg/kg, 14 days) to individuals with the African Variant
(A-) of G6PD-deficiency [10]. The observed reduction in Hb
concentration indicates a small but genuine risk of PQ use in
individuals who are anaemic prior to drug administration. The risk
to the individual patient has to be weighted against the potential
benefit of a reduced malaria transmission. In the current study, we
excluded individuals with an Hb,8 g/dL. The risk of anaemia is
likely to be increased in individuals with lower pre-treatment Hb
concentrations, which is important since Hb is not routinely
determined prior to treatment. In case of mass-administration of
SP+AS+PQ, anaemic individuals should preferably be identified
prior to treatment and excluded from PQ treatment. This can be
done by HemocueH which allows a rapid and reliable assessment
of anaemia in the field [33]. Areas of low and seasonal malaria
transmission are those that are most likely to benefit from MDA.
In these areas, the prevalence of severe anaemia prior to the
malaria season is likely to be low [34]. In these circumstances we
consider the addition of a single dose of PQ to SP+AS to be a safe
approach to reduce post-treatment malaria transmission.
Overall evidence
This is the first study that determines the effect of PQ on
submicroscopic gametocyte densities and our findings are in line
with previous studies that where PQ efficiently cleared microscopic
gametocyte concentrations [10,11,35–37]. The addition of a single
dose of PQ had no beneficial influence on the clearance of asexual
parasites, as was described previously [36,38].
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